Overview

This trial is active, not recruiting.

Condition obesity
Treatments beta3-adrenergic receptor agonist, placebo
Phase phase 2
Sponsor Aaron Cypess
Collaborator National Institutes of Health (NIH)
Start date February 2013
End date December 2015
Trial size 15 participants
Trial identifier NCT01783470, 2012-P-000309, 2P30DK036836-26

Summary

This study will test the hypothesis that human brown adipose tissue (BAT) can be activated using a β3-adrenergic receptor (AR) agonist. The efficacy of β3-AR agonist will be compared with cold exposure, which we have already shown can activate human BAT, as well as a placebo control.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification pharmacodynamics study
Intervention model crossover assignment
Masking open label
Primary purpose basic science
Arm
(Placebo Comparator)
lactose
placebo Lactose
(Experimental)
single dose
beta3-adrenergic receptor agonist
single dose

Primary Outcomes

Measure
BAT activity as measured by 18F-FDG PET/CT
time frame: 60 min after FDG administration

Secondary Outcomes

Measure
plasma norepinephrine
time frame: 5 minutes before FDG administration

Eligibility Criteria

Male participants from 18 years up to 65 years old.

Inclusion Criteria: - Healthy Male - 18-65 years old - BMI between 18-40 - Not participated in clinical trial and received either an investigational or marketed drug within two months prior to the study - Not donated blood in previous two months Exclusion Criteria: - Women - History of local or systemic infection disease with fever or requiring antibiotic within 4 weeks of drug administration - Corrected QT interval above normal - Laboratory test results that is more than 1.5 fold outside normal range and/or is judged to be clinically significant - Current addition to alcohol or substances of abuse - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation - Use of system course of corticosteroids or other medication known to cause insulin resistance in previous 6 weeks - Hyperthyroidism,hypothyroidism, hypertension (even if controlled with medications), heart disease (including CAD and CHF), cardiac arrhythmias, diabetes, unstable vasomotor system, or use of monoamine oxidase (MAO) inhibitors - Diagnosis of bladder outlet obstruction or use of any medication to treat overactive bladder (e.g. Tolterodine, Solifenacin, Propiverine, Oxybutynin, and Fesoterodine)

Additional Information

Official title Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue
Principal investigator Aaron M Cypess, MD, PhD
Description This study will include an outpatient screening visit and three separate, independent overnight study visits in the General Clinical Research Center (GCRC) at Beth Israel Deaconess Medical Center (BIDMC). Screening procedures will consist of a medical history, physical examination, blood draw, and ECG. If, from the screening tests, it is determined that the eligibility criteria have been meet, healthy volunteers will participate in three separate inpatient visits at BIDMC. Study procedures will occur in the GCRC and the Nuclear Medicine suite at BIDMC. Volunteers will first complete Day A, in which we will measure BAT volume and activity during cold exposure. Cold exposure will consist of wearing a cooling vest at 55 - 61°F, a temperature shown to be cool enough to activate brown adipose tissue but warm enough not to lead to shivering. Resting metabolic rate (RMR) will be measured by indirect calorimetry before and during cool exposure. If there is detectable brown fat activity on Day A, volunteers will participate in Days B and C. Days B and C will be conducted in random order to reduce any bias from the sequence of treatment and scans, as well as any potential placebo effects. Day B will consist of pharmacological stimulation with β3-AR agonist. On Day C, volunteers will be given a placebo control and will not undergo cooling. A blood draw of 26 cc will always be done prior to FDG injection and FDG PET/CT will always be performed 60 minutes after FDG injection. On Day A, FDG will be injected after 60 minutes of cool exposure and the volunteer will remain in the cooling vest for another 60 minutes after FDG injection. To compare energy expenditure and BAT mass and activity among volunteers, we will normalize the data to fat and muscle mass. Whole-body and regional fat and muscle mass will be measured via a Dual Energy X-ray Absorptiometry (DXA) scan at the end of Day A.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Beth Israel Deaconess Medical Center.